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Background
In BLT (bone marrow-liver-thymus) humanized mice,
human thymocytes are educated by autologous human
thymic tissue, resulting in functional human T cells cap-
able of rapidly selecting for CTL escape mutations in
HIV. In contrast, limitations to B cell maturation have
been noted. But despite this, we show for the first time
that HIV infected BLT mice can produce class-switched
anti-HIV antibodies with neutralizing activities.
Methods
Humanized BLT mice were generated by transplanting
irradiated NOD-scid/IL2rgnull (NSG) mice with fetal
thymus and liver fragments and then injecting them
with autologous human CD34+ stem cells. BLT mice
were then infected with HIVJRCSF and bled at various
time-points. HIV neutralizing activity was measured
using Tat-induced luciferase reporter TZM-bl cells.
Results
Human transitional B cells were present in greater fre-
quencies in BLT mice than adult humans. Most of these
cells had a T1 phenotype in the blood and spleen. But
despite this B cell maturation defect, class-switched IgG
Abs against various HIV proteins were detected by Wes-
tern Blot in HIV-infected BLT mice. Using ELISA to
determine anti-p24 IgG Ab titers, Abs were present as
early as 8 weeks post infection (p.i.), with peak Ab titers
seen after 15 weeks. One infected mouse demonstrated a
peak titer similar to that seen in a chronically infected
human. Finally, plasma samples from infected BLT mice
after 22 weeks p.i. demonstrated neutralizing activities
against the challenge virus. Average IC50 neutralizing
titers in these mice were similar to those from infected
human samples.
Conclusion
The ability of humanized BLT mice to generate func-
tional humoral immune responses may be further
improved by strategies to improve their B cell matura-
tion, which will further improve the potential of these
mice to become a model system to study candidate HIV
vaccines and therapies.
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